Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company Drug

Nanjing Sanhome’s Oritinib Wins NMPA Approval for EGFR T790M Positive NSCLC

Fineline Cube Jun 18, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA)...

Company Drug

MicroPort Endovascular’s Vewatch Filter Gets NMPA Green Light for Pulmonary Embolism Prevention

Fineline Cube Jun 18, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical device company, has announced...

Company Drug

Kintor Pharmaceutical Initiates Phase II Clinical Trial for Acne Treatment GT20029 in China

Fineline Cube Jun 18, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the enrollment...

Company Drug

RemeGen’s Telitacicept Receives NMPA Approval for Clinical Trial in IgG4 Related Diseases

Fineline Cube Jun 18, 2024

RemeGen (HKG: 9995), a Chinese pharmaceutical company, has announced that it has received clinical trial...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Breast Cancer Drug Combo

Fineline Cube Jun 18, 2024

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that it...

Company Deals

Shineco Partners with Tuling Vision to Develop Intelligent Healthcare Solutions

Fineline Cube Jun 18, 2024

Shineco Inc. (NSDQ: SISI), a U.S.-based company, has signed a partnership deal with China-headquartered Tuling...

Company Deals

Wuxi’s Binhu District Partners with Fresenius Kabi to Boost Healthcare Services

Fineline Cube Jun 18, 2024

The Binhu District People’s Government of Wuxi, Jiangsu province, China, has entered into a partnership...

Company Drug

Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Phase II Trial in Pancreatic Cancer

Fineline Cube Jun 18, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...

Company Drug

Walvax Biotechnology Halts COVID-19 Vaccine Clinical Trials Citing Low Benefits

Fineline Cube Jun 18, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...

Company Drug

Sichuan Kelun-Biotech Receives NMPA Clearance for SKB518 Clinical Trial in Solid Tumors

Fineline Cube Jun 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...

Company Deals

Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development

Fineline Cube Jun 18, 2024

Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with...

Company Drug

BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US

Fineline Cube Jun 18, 2024

BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...

Company Drug

Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials

Fineline Cube Jun 18, 2024

Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...

Company Drug

Amgen’s Blincyto Secures New Indication Approval for B-ALL Consolidation Treatment in the US

Fineline Cube Jun 18, 2024

Amgen (NASDAQ: AMGN) has announced that its bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received...

Company Drug

MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma

Fineline Cube Jun 18, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company

AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer

Fineline Cube Jun 17, 2024

Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...

Company Drug

FDA Approves Broadened Use of BMS’ Next-Gen TKI Augtyro for Advanced Solid Tumors

Fineline Cube Jun 17, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Deals

CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally

Fineline Cube Jun 17, 2024

CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced...

Company Deals

Neusoft IntelliRay Secures Over RMB 100 Million in Series C Funding Round

Fineline Cube Jun 17, 2024

Neusoft IntelliRay Technology Co., Ltd, a medical technology company based in Shenyang, has successfully closed...

Company Deals Drug

Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories

Fineline Cube Jun 17, 2024

Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an...

Posts pagination

1 … 389 390 391 … 711

Recent updates

  • METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.